PRGONYSEPharmaceutical PreparationsFiscal year ends December 31

PERRIGO Co plc

Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Aug 5, 2026

$16.09−0.54 (-3.25%)

Close on Oct 19, 2026

Market cap: $2.25B
P/E (TTM): –
Dividend yield: 7.21%

Fundamental chart

Pick a measure to chart its full history

$4.25BFY2025, +118.1% a year since FY2013

Where these numbers come from

Parsed from the XBRL in Perrigo's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on Aug 26, 1993
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PRGO.

Revenue growth-4.2% · median 4.4%

Gross margin33.3% · median 52.7%

Operating margin-37.7% · median 10.3%

Net margin-41.9% · median 4.4%

Company	Revenue	Growth
VTRS	$14.74B	+4.4%
OGN	$6.13B	-2.5%
PRGO	$4.14B	-4.2%
AMRX	$3.12B	+9.3%
PBH	$1.10B	-1.4%
NATR	$492.02M	+6.8%

Company

Next earnings (est.): Nov 4, 2026, before open
Exchange: NYSE
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 8,100
Held by institutions: 100.0%
Auditor: Ernst & Young LLP
SEC CIK: 1585364

Advertisement
300 × 250